Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Sep 1;34(9):1508-1511.
doi: 10.1681/ASN.0000000000000167. Epub 2023 Jul 4.

Blood-Brain Barrier Permeability in ESKD-A Proof-of-Concept Study

Aditi Gupta  1   2   3 , Aanya Bansal  2 , Kate Young  4 , Archana Gautam  2 , Joseph Donald  5 , Branden Comfort  2 , Robert Montgomery  4
Affiliations

Blood-Brain Barrier Permeability in ESKD-A Proof-of-Concept Study

Aditi Gupta et al. J Am Soc Nephrol. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

A. Gupta reports consultancy: Novartis Pharmaceuticals; research funding: NIH, Novartis Pharmaceuticals, and Veloxis pharmaceuticals; honoraria: Uptodate; advisory or leadership role: Kidney Medicine—editorial board and National Kidney Foundation—member of regional medical advisory board. No payment was received through any of these positions; and speakers bureau: Bayer Pharmaceuticals. K. Young reports ownership interest: ICON plc. All remaining authors have nothing to disclose.

Figures

Figure 1.
Figure 1.
Scatterplots displaying individual participants' mean SUV in the ESKD and control groups. (A) Box and whisker plots for SUV in ESKD and control groups. (B) SUV as a function of age and group (controls: yellow circles, ESKD: blue circles). The dashed lines represent the estimated group means across age. SUV, standardized uptake value.
See this image and copyright information in PMC

References

    1. Nation DA Sweeney MD Montagne A, et al. . Blood-brain barrier breakdown is an early biomarker of human cognitive dysfunction. Nat Med. 2019;25(2):270–276. doi:10.1038/s41591-018-0297-y - DOI - PMC - PubMed
    1. Bobot M Thomas L Moyon A, et al. . Uremic toxic blood-brain barrier disruption mediated by AhR activation leads to cognitive impairment during experimental renal dysfunction. J Am Soc Nephrol. 2020;31(7):1509–1521. doi:10.1681/ASN.2019070728 - DOI - PMC - PubMed
    1. Chagnot A, Barnes SR, Montagne A. Magnetic resonance imaging of blood-brain barrier permeability in dementia. Neuroscience. 2021;474:14–29. doi:10.1016/j.neuroscience.2021.08.003 - DOI - PMC - PubMed
    1. Martino F, Amici G, Rosner M, Ronco C, Novara G. Gadolinium-based contrast media nephrotoxicity in kidney impairment: the physio-pathological conditions for the perfect murder. J Clin Med. 2021;10(2):271. doi:10.3390/jcm10020271 - DOI - PMC - PubMed
    1. Grobner T. Gadolinium--a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant. 2006;21(4):1104–1108. doi:10.1093/ndt/gfk062 - DOI - PubMed

Publication types

LinkOut - more resources